ES8506451A1 - Procedimiento para preparar vacunas polivalentes adsorbidas y liofilizadas - Google Patents

Procedimiento para preparar vacunas polivalentes adsorbidas y liofilizadas

Info

Publication number
ES8506451A1
ES8506451A1 ES529961A ES529961A ES8506451A1 ES 8506451 A1 ES8506451 A1 ES 8506451A1 ES 529961 A ES529961 A ES 529961A ES 529961 A ES529961 A ES 529961A ES 8506451 A1 ES8506451 A1 ES 8506451A1
Authority
ES
Spain
Prior art keywords
lyophilized
value
preparation
adsorbed
polyvalent vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES529961A
Other languages
English (en)
Other versions
ES529961A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Oltoanyagtermelo Es Kutato Intezet
Original Assignee
Human Oltoanyagtermelo Es Kutato Intezet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Oltoanyagtermelo Es Kutato Intezet filed Critical Human Oltoanyagtermelo Es Kutato Intezet
Publication of ES8506451A1 publication Critical patent/ES8506451A1/es
Publication of ES529961A0 publication Critical patent/ES529961A0/es
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

METODO DE PREPARACION DE VACUNAS POLIVALENTES ADSORBIDAS Y LIOFILIZADAS. CONSISTE EN LA ADSORCION DE ANTIGENOS DE TETANO, DIFTERIA, PERTUSSIS Y, OPCIONALMENTE, TIFUS, CONCENTRADOS A 5-15 DOSIS/3 ML., A UN PH DE 3-6, EN UN VEHICULO INSOLUBLE CONCENTRADO DEL MISMO MODO QUE LOS ANTIGENOS, QUE PUEDE SER FOSFATO DE ALUMINIO O HIDROXIDO DE ALUMINIO; SEGUIDO DEL AJUSTE DEL PH A 5-6 Y DE LA LIOFILIZACION DE LA MEZCLA JUNTO CON UN MATERIAL PROTECTOR, NORMALMENTE UTILIZADO EN LAS TECNICAS DE LIOFILIZACION.TIENE APLICACION PARA LA PREPARACION DE VACUNAS POLIVALENTES QUE PUEDEN SER ALMACENADAS BAJO DIVERSAS CONDICIONES CLIMATICAS, DURANTE UN PERIODO DE TIEMPO SUFICIENTEMENTE LARGO.
ES529961A 1983-02-22 1984-02-22 Procedimiento para preparar vacunas polivalentes adsorbidas y liofilizadas Granted ES529961A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU83609A HU188847B (en) 1983-02-22 1983-02-22 Process for producing liophylized combined vaccines

Publications (2)

Publication Number Publication Date
ES8506451A1 true ES8506451A1 (es) 1985-07-16
ES529961A0 ES529961A0 (es) 1985-07-16

Family

ID=10950430

Family Applications (1)

Application Number Title Priority Date Filing Date
ES529961A Granted ES529961A0 (es) 1983-02-22 1984-02-22 Procedimiento para preparar vacunas polivalentes adsorbidas y liofilizadas

Country Status (18)

Country Link
US (1) US4578270A (es)
JP (1) JPS59196821A (es)
BE (1) BE898955A (es)
CA (1) CA1234048A (es)
CH (1) CH663901A5 (es)
CS (1) CS272759B2 (es)
DD (1) DD216384A5 (es)
DE (1) DE3406419A1 (es)
DK (1) DK82784A (es)
ES (1) ES529961A0 (es)
FR (1) FR2541116B1 (es)
GB (1) GB2135190B (es)
HU (1) HU188847B (es)
IT (1) IT1196032B (es)
NL (1) NL8400511A (es)
PL (1) PL246306A1 (es)
PT (1) PT78132B (es)
YU (1) YU33284A (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU188847B (en) * 1983-02-22 1986-05-28 Human Oltoanyagtermeloe Es Kutato Intezet,Hu Process for producing liophylized combined vaccines
JPS62162963A (ja) * 1986-01-10 1987-07-18 Sadao Shiosaka 金属コロイド粒子を担体とする低分子物質に対する特異抗体の作成法
GB8601279D0 (en) * 1986-01-20 1986-02-26 Public Health Lab Service Purification of pertussis antigens
US4762710A (en) * 1986-06-16 1988-08-09 The United States Of America As Represented By The Department Of Health And Human Services Novel method of preparing toxoid by oxidation and metal ions
US5139776A (en) * 1987-04-24 1992-08-18 The Research Foundation For Microbial Diseases Of Osaka University Method for culturing Bordetella pertussis, a pertussis toxoid and a pertussis vaccine
CA1337859C (en) * 1987-04-24 1996-01-02 Masashi Chazono Method for culturing bordetella pertussis, a pertussis toxoid and a pertussis vaccine
US5290563A (en) * 1989-07-27 1994-03-01 Laboratoire Des Stallergenes Method for combining a mixture of heterogeneous substances with liposomes
MX170503B (es) * 1990-05-10 1993-08-26 Univ Mexico , "procedimiento para obtener un reactivo antigenico util para determinar indirectamente salmonella typhi.
GB9125695D0 (en) * 1991-12-03 1992-01-29 Mastavac Limited Medical preparations
WO1994015636A1 (en) * 1993-01-08 1994-07-21 Csl Limited Vaccine preparations
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
US20010055581A1 (en) * 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US7229841B2 (en) * 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
GB2342922B (en) * 1998-10-19 2002-12-24 Jeyes Group Plc Lavatory cleansing block
RU2277905C2 (ru) * 1999-08-24 2006-06-20 Тева Фармасьютикал Индастриз, Лтд. Вакцинная композиция и способ ее применения
US6592869B2 (en) * 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
CN1331532C (zh) * 2000-02-08 2007-08-15 阿勒根公司 肉毒杆菌毒素药物组合物
US20030138460A1 (en) * 2000-02-08 2003-07-24 Allergan, Inc Methods of treating animals with botulinum toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
JP2003535119A (ja) * 2000-06-08 2003-11-25 パウダージェクト ワクチンズ，インコーポレーテッド 粉末組成物
US20040213798A1 (en) * 2000-06-08 2004-10-28 Powderject Vaccines, Inc. Spray-dried alum compositions
US20020120228A1 (en) * 2000-06-08 2002-08-29 Yuh-Fun Maa Powder compositions
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
AU2002302814A1 (en) * 2001-06-08 2002-12-23 Powderject Vaccines, Inc. Spray freeze-dried compositions
JP2008504216A (ja) * 2003-12-02 2008-02-14 サイトイミューン サイエンシズ インコーポレイテッド モノクローナル抗体の生成のための方法および組成物
CN1960825A (zh) * 2004-01-28 2007-05-09 细胞免疫科学公司 官能化胶态金属组合物和方法
EP2324850A1 (en) 2005-10-04 2011-05-25 Alk-Abelló A/S Solid vaccine formulation
US20110014118A1 (en) * 2007-09-21 2011-01-20 Lawrence Tamarkin Nanotherapeutic colloidal metal compositions and methods
US20090104114A1 (en) * 2007-09-21 2009-04-23 Cytimmune Sciences, Inc. Nanotherapeutic Colloidal Metal Compositions and Methods
CA2706700A1 (en) * 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0916570D0 (en) * 2009-09-21 2009-10-28 Royal Holloway & Bedford New C Method

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2085391A (en) * 1934-01-31 1937-06-29 Sharp & Dohme Inc Lyophilic biologically active substances and process of producing the same
US3097140A (en) * 1958-10-31 1963-07-09 Merck & Co Inc Preparing a mixed polio, pertussis, tetanus, and diphtheria vaccine with benzethonium chloride
GB895073A (en) * 1959-11-23 1962-05-02 Wellcome Found Immunising preparations containing clostridium perfringens toxins and toxoids
US3395219A (en) * 1964-12-11 1968-07-30 Merck & Co Inc Process for production of pertussis antigen
NL6600706A (es) * 1965-02-05 1966-08-08
GB1081796A (en) * 1965-08-13 1967-08-31 Wright Fleming Inst Of Microbi Improvements in or relating to oily adjuvants for water-in-oil emulsions of antigenic materials
US3405218A (en) * 1965-09-22 1968-10-08 Parke Davis & Co Extracting bordetella pertussis antigens with lithium bromide
GB1145320A (en) * 1966-05-20 1969-03-12 Ustav Ser A Ockovacich Latek O Process for the preparation of bacterial cultures for vaccines against pertussis and
GB1152607A (en) * 1967-03-08 1969-05-21 Pfizer Ltd Antigenic Compositions
GB1218277A (en) * 1968-08-20 1971-01-06 Miles Lab Dry water-dispersible aluminium hydroxide gels
US3599150A (en) * 1969-08-01 1971-08-10 Miles Lab Stabilized aluminum hydroxide suspensions
FR2181426B1 (es) * 1972-04-06 1974-12-20 Pasteur Institut
FR2227861B1 (es) * 1973-05-04 1976-07-02 Anvar
DE2355094C3 (de) * 1973-11-03 1979-05-23 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines Tetanus-Impfstoffs
DE2461439C3 (de) * 1974-12-24 1980-03-20 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines schützenden Antigens von Bordetella Pertussis sowie jenes enthaltendes Mittel
JPS5296729A (en) * 1976-02-05 1977-08-13 Shionogi & Co Ltd Mixed vaccin for cyanomycosis
US4273762A (en) * 1979-12-03 1981-06-16 Merck & Co., Inc. Lyophilization process for live viral compositions
HU188847B (en) * 1983-02-22 1986-05-28 Human Oltoanyagtermeloe Es Kutato Intezet,Hu Process for producing liophylized combined vaccines

Also Published As

Publication number Publication date
GB2135190A (en) 1984-08-30
GB8403921D0 (en) 1984-03-21
JPS59196821A (ja) 1984-11-08
DK82784A (da) 1984-08-23
BE898955A (fr) 1984-08-20
US4578270A (en) 1986-03-25
PL246306A1 (en) 1985-02-27
CS122584A2 (en) 1990-06-13
CH663901A5 (de) 1988-01-29
FR2541116B1 (fr) 1988-07-15
YU33284A (en) 1987-10-31
GB2135190B (en) 1986-10-22
PT78132A (en) 1984-03-01
FR2541116A1 (fr) 1984-08-24
DK82784D0 (da) 1984-02-21
HU188847B (en) 1986-05-28
ES529961A0 (es) 1985-07-16
IT8419729A0 (it) 1984-02-21
IT1196032B (it) 1988-11-10
NL8400511A (nl) 1984-09-17
CS272759B2 (en) 1991-02-12
CA1234048A (en) 1988-03-15
DE3406419A1 (de) 1984-08-23
DD216384A5 (de) 1984-12-12
PT78132B (en) 1986-05-19

Similar Documents

Publication Publication Date Title
ES8506451A1 (es) Procedimiento para preparar vacunas polivalentes adsorbidas y liofilizadas
GB1502774A (en) Immunological preparations
SE8903777L (sv) Liposome/doxorubicin, komposition och foerfarande
CS419786A2 (en) Method of grippal vaccine production
LU90203I2 (fr) Anatoxine diphtérique anatoxine tétanique trois antigènes coquelucheux purifiés (toxine pertussique tp hémagglutinine filamenteuse (haf) et pertactine (protéine de membrane externe 69 kd) et le principal antigène de surface du virus de l'hépatite b (vhb) purfié (infanrix hepb) et ses dérivés pharmaceutiquement acceptables
GB1422973A (en) Process for preparing adsorbed vaccines
ES8608883A1 (es) Procedimiento de preparacion de un conjugado de muramilpeptido y de un hapteno o fragmento haptenico de bajo peso molecular.
NZ335384A (en) Acellular pertussis vaccine with diphthriae and tetanus toxoids
ES470855A1 (es) Un procedimiento de obtencion de una preparacion de gamma- globulina nativa liofilizada
IE781880L (en) Immunogenic herpes virus subunit
GR3029884T3 (en) Method of preparing a radioactive rhenium complex solution.
SE7602871L (sv) Vaccin for aktiv immunisering
FI932759A0 (fi) Anvaendningen av IL-4 foer oekning av pao vacciners immunogener verkande immunreaktioner
SE8400934D0 (sv) Forfarande for framstellning av lyofiliserade, adsorberade, polyvalenta vacciner
US3141824A (en) Pertussis antigen
CA1209036A (en) Combined haemophilus influenzae and diphtheria, pertussis, tetanus vaccine
EP0414816A4 (en) Induction of tolerance to a foreign antigen
PT69953A (en) Process for preparing a composition comprising a lyophilized herpes virus
SOMEYA et al. Studies on the adequate composition of diphtheria and tetanus toxoids—with reference to the amounts of toxoids and aluminum adjuvant
Tokumaru Further analysis of physicochemical and immunologic properties of herpes simplex virus precipitating antigens
ATE111485T1 (de) Peptidbehandlung von hartnäckigen infektionskrankheiten.
GB2001995A (en) An immunostimulant, a process for preparing it, and compositions containing it
IL61278A (en) Process for preparing specific antigen vaccine for transmissible gastroenteritis(tge)in swine
GB1536725A (en) Preparation of a blood protein fraction
SU1218526A1 (ru) Способ получения мелиоидозной преципитирующей сыворотки

Legal Events

Date Code Title Description
MM4A Patent lapsed

Effective date: 19960506